首页> 外文期刊>European Journal of Pediatric Surgery Reports >Pancreatic Kaposiform Hemangioendothelioma Not Responding to Sirolimus
【24h】

Pancreatic Kaposiform Hemangioendothelioma Not Responding to Sirolimus

机译:对西罗莫司无反应的胰腺卡波状肝血管内皮瘤

获取原文
       

摘要

Background Kaposiform hemangioendothelioma (KHE) is a vascular tumor frequently associated with Kasabach–Merritt phenomenon (KMP), characterized by severe thrombocytopenia and consumptive coagulopathy. Visceral involvement in KHE is rare. In our recent experience, sirolimus has shown to be an effective treatment in cutaneous KHE, becoming indeed the treatment of choice in KMP. We report a case of pancreatic KHE associated with KMP and refractory to sirolimus. Case Report A 4-month-old infant is referred for obstructive jaundice (10 mg/dL conjugated bilirubin) secondary to vascular pancreatic tumor. Magnetic resonance (MR) and immunohistochemistry were compatible with KHE, but the tumor was considered unresectable. We initiated sirolimus (0.8 mg/m 2 /12 h) to treat KMP, and interventional radiology was performed for percutaneous biliary diversion. This procedure prompted KMP (platelets: 51,000/μL). Sirolimus treatment for 7 days showed no effect; therefore, we started our VAT protocol (vincristine/aspirine/ticlopidin) with great response after 10 days (platelets: 3,70,000/μL). Three months later, percutaneous biliary diversion was replaced by a biliary stent. The tumor disappeared leaving fibrosis and dilatation of biliary tract needing hepaticojejunostomy 6 months later. Discussion It is difficult to establish protocols for an unusual presentation of a tumor with different targets. This is a reason collaborative multicenter studies should be performed. Management of obstructive jaundice secondary to a tumor that usually regresses in 10 years is an added challenge; therefore, the management should be led by a multidisciplinary team. Sirolimus treatment in cutaneous KHE has been described as successful in the literature, as well as in our own experience; however, it failed in our first patient with visceral KHE. We need to investigate the different response to pharmacological agents in tumors with similar histopathology, but with visceral involvement.
机译:背景Kapo​​siform血管内皮细胞瘤(KHE)是一种血管肿瘤,常与卡萨巴赫-梅里特现象(KMP)有关,特征是严重的血小板减少和消耗性凝血病。内脏参与KHE的情况很少。根据我们最近的经验,西罗莫司已被证明是治疗皮肤KHE的有效方法,实际上已成为KMP的首选治疗方法。我们报告一例胰腺KHE与KMP有关,对西罗莫司难治。病例报告4个月大的婴儿因血管性胰腺肿瘤继发阻塞性黄疸(10 mg / dL结合胆红素)而转诊。磁共振(MR)和免疫组化与KHE兼容,但肿瘤被认为无法切除。我们开始使用西罗莫司(0.8 mg / m 2 / 12 h)治疗KMP,并经介入放射学检查经皮胆道改道。此步骤提示使用KMP(血小板:51,000 /μL)。西罗莫司治疗7天无效果。因此,我们开始使用VAT方案(长春新碱/阿司匹林/提洛匹定)后10天(血小板:3,70,000 /μL)反应良好。三个月后,经皮胆道改道被胆道支架代替。 6个月后,肿瘤消失,剩下的纤维化和胆道扩张需要进行肝空肠吻合术。讨论难以建立具有不同靶标的肿瘤异常表现的方案。这就是进行协作式多中心研究的原因。继发于通常在10年内消退的肿瘤继发的梗阻性黄疸的治疗是一个额外的挑战。因此,管理应该由一个多学科团队领导。在文献以及我们自己的经验中,在皮肤KHE中使用西罗莫司治疗都是成功的。但是,它在我们的首位内脏KHE患者中失败了。我们需要研究具有相似组织病理学但内脏受累的肿瘤对药理学药物的不同反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号